Advances and challenges in eliminating mother-to-child transmission of hepatitis B virus worldwide

Hongqiao ZHENG; Ailing WANG

doi:10.12449/JCH241104

Volume 40 Issue 11

Nov. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(11): 2152-2157

PDF( 672 KB)

Advances and challenges in eliminating mother-to-child transmission of hepatitis B virus worldwide

DOI: 10.12449/JCH241104

Hongqiao ZHENG¹,
Ailing WANG^{2
,
,
,}

1.
Chinese Center for Disease Control and Prevention，Beijing 102206，China
2.
National Center for Women and Children’s Health，NHC，PRC，Beijing 100081，China

More Information

Corresponding author: Wang Ailing， ailing@chinawch.org.cn （ORCID： 0000-0003-4801-6186）
Received Date: 2024-09-13
Accepted Date: 2024-10-11
Published Date: 2024-11-25

Abstract

Abstract

At present， there are policies for hepatitis B testing in 89.8% of countries and regions around the world. In 2022， the global hepatitis B vaccine birth dose coverage reached 45%， while the third-dose coverage reached 85%. Approximately 3% of pregnant women with high viral loads have received antiviral therapy， and the prevalence rate of HBsAg is about 0.7% among children aged≤5 years. While significant progress has been made in various countries towards eliminating mother-to-child transmission of hepatitis B virus （HBV）， there are still large gaps across countries and numerous challenges. There are differences in the prevalence of hepatitis B， vaccination， and access to antiviral drugs across the globe， and in addition， the factors such as insufficient laboratory testing capacity and difficulties in ensuring sustained access to treatment among pregnant and parturient women with HBV infection pose obstacles to eliminating the mother-to-child transmission of HBV.
- Hepatitis B Virus,
- Infectious Disease Transmission， Vertical,
- Disease Eradication

FullText(HTML)

References(45)

References

[1]	World Health Organization. Hepatitis B[EB/OL].( 2024-04-09)[ 2024-09-21]. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
[2]	THIO CL, GUO N, XIE C, et al. Global elimination of mother-to-child transmission of hepatitis B: Revisiting the current strategy[J]. Lancet Infect Dis, 2015, 15( 8): 981- 985. DOI: 10.1016/S1473-3099(15)00158-9.
[3]	Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: A modelling study[J]. Lancet Gastroenterol Hepatol, 2023, 8( 10): 879- 907. DOI: 10.1016/S2468-1253(23)00197-8.
[4]	KFUTWAH AK, TEJIOKEM MC, NJOUOM R. A low proportion of HBeAg among HBsAg-positive pregnant women with known HIV status could suggest low perinatal transmission of HBV in Cameroon[J]. Virol J, 2012, 9: 62. DOI: 10.1186/1743-422X-9-62.
[5]	RAMOS JM, TORO C, REYES F, et al. Seroprevalence of HIV-1, HBV, HTLV-1 and Treponema pallidum among pregnant women in a rural hospital in Southern Ethiopia[J]. J Clin Virol, 2011, 51( 1): 83- 85. DOI: 10.1016/j.jcv.2011.01.010.
[6]	WANG XY, LIU J, WANG Q, et al. Economic-related inequalities in hepatitis B virus infection among 115.8 million pregnant women in China from 2013 to 2020[J]. EClinicalMedicine, 2022, 49: 101465. DOI: 10.1016/j.eclinm.2022.101465.
[7]	NARTEY YA, OKINE R, SEAKE-KWAWU A, et al. A nationwide cross-sectional review of in-hospital hepatitis B virus testing and disease burden estimation in Ghana, 2016-2021[J]. BMC Public Health, 2022, 22( 1): 2149. DOI: 10.1186/s12889-022-14618-3.
[8]	E B, KO K, KIM R, et al. Residual risk of mother-to-child transmission of HBV despite timely hepatitis B vaccination: A major challenge to eliminate hepatitis B infection in Cambodia[J]. BMC Infect Dis, 2023, 23( 1): 261. DOI: 10.1186/s12879-023-08249-1.
[9]	PORNGASEMSART Y, SIRILERT S, TONGSONG T. Change in prevalence of hepatitis B virus infection in pregnant women in the last two decades in Thailand[J]. Viruses, 2024, 16( 2): 314. DOI: 10.3390/v16020314.
[10]	BAILEY H, NASTOULI E, WEBB S, et al. Characteristics, treatment and care of pregnant women living with hepatitis B in England: Findings from a national audit[J]. Epidemiol Infect, 2023, 151: e50. DOI: 10.1017/S0950268823000225.
[11]	Pan American Health Organization. EMTCT Plus: Framework for elimination of mother-to-child transmission of HIV, Syphilis, Hepatitis B, and Chagas[EB/OL].[ 2024-10-25]. https://iris.paho.org/bitstream/handle/10665.2/34306/PAHOCHA17009-eng.pdf?sequence=1&isAllowed=y. https://iris.paho.org/bitstream/handle/10665.2/34306/PAHOCHA17009-eng.pdf?sequence=1&isAllowed=y
[12]	World Health Organization Regional Office for the Western Pacific. Regional framework for the triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis in Asia and the Pacific, 2018-2030[R]. Manila: WHO Regional Office for the Western Pacific, 2018.
[13]	World Health Organization. Prevention of mother-to-child transmission of hepatitis B virus: Guidelines on antiviral prophylaxis in pregnancy[R/OL].( 2020-12-27)[ 2024-09-21]. https://www.who.int/publications/i/item/978-92-4-000270-8. https://www.who.int/publications/i/item/978-92-4-000270-8
[14]	World Health Organization. Global guidance on criteria and processes for validation: elimination of mother-to-child transmission of HIV, syphilis and hepatitis B virus[R]. Geneva: World Health Organization, 2021.
[15]	World Health Organization. Viral hepatitis B and C burden of disease, policy adoption and implementation status in WHO regions, 2024[EB/OL].[ 2024-10-25]. https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/j0482-who-ias-hep_factsheet_v3.pdf. https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/j0482-who-ias-hep_factsheet_v3.pdf
[16]	Department of Maternal and Child Health, National Health Commission of the People’s Republic of China. Notice of the General Office of the National Health Commission on the issuance of work norms for the prevention of mother-to-child transmission of HIV, syphilis and hepatitis B(2020 edition)[EB/OL].( 2020-11-25)[ 2024-09-21]. http://www.nhc.gov.cn/fys/s3581/202011/fc7b46b2b48b45a69bd390ae3a62d065.shtml. http://www.nhc.gov.cn/fys/s3581/202011/fc7b46b2b48b45a69bd390ae3a62d065.shtml 国家卫生健康委员会妇幼健康司. 国家卫生健康委办公厅关于印发预防艾滋病、梅毒和乙肝母婴传播工作规范(2020年版)的通知[EB/OL].( 2020-11-25)[ 2024-09-21]. http://www.nhc.gov.cn/fys/s3581/202011/fc7b46b2b48b45a69bd390ae3a62d065.shtml. http://www.nhc.gov.cn/fys/s3581/202011/fc7b46b2b48b45a69bd390ae3a62d065.shtml
[17]	OLAKUNDE BO, ADEYINKA DA, NDUKWE CD, et al. Antenatal hepatitis B screening in Nigeria: A comparative analysis with syphilis and HIV[J]. Int J STD AIDS, 2021, 32( 14): 1290- 1297. DOI: 10.1177/09564624211035922.
[18]	World Health Organization. Hepatitis B vaccines: WHO position paper, July 2017-Recommendations[J]. Vaccine, 2019, 37( 2): 223- 225. DOI: 10.1016/j.vaccine.2017.07.046.
[19]	NGUYEN HT, THAVORNCHAROENSAP M, PHUNG TL, et al. Comparative efficacy and safety of pharmacologic interventions to prevent mother-to-child transmission of hepatitis B virus: A systematic review and network meta-analysis[J]. Am J Obstet Gynecol, 2022, 227( 2): 163- 172. DOI: 10.1016/j.ajog.2022.02.042.
[20]	DING ZR, KANG WY, LU L, et al. Evaluation on the efficacy of prevention programs and relevant factors targeting mother-to-infant transmission on hepatitis B virus in Yunnan province[J]. Chin J Epidemiol, 2014, 35( 2): 114- 116. DOI: 10.3760/cma.j.issn.0254-6450.2014.02.002. 丁峥嵘, 康文玉, 陆林, 等. 云南省乙型肝炎母婴阻断实施效果评价[J]. 中华流行病学杂志, 2014, 35( 2): 114- 116. DOI: 10.3760/cma.j.issn.0254-6450.2014.02.002.
[21]	WANG H, FANG JW, GU ZW, et al. Application of hepatitis B immunoglobulin in prevention of mother-to-child transmission of chronic hepatitis B in HBsAg- and HBeAg-positive mother[J]. J Obstet Gynaecol, 2022, 42( 5): 877- 882. DOI: 10.1080/01443615.2021.1946495.
[22]	World Health Organization. Hepatitis B(HepB3) immunization coverage among 1-year-olds(%)[EB/OL].[ 2024-09-21]. https://www.who.int/data/gho/data/indicators/indicator-details/GHO/hepatitis-b-(hepb3)-immunization-coverage-among-1-year-olds-(-). https://www.who.int/data/gho/data/indicators/indicator-details/GHO/hepatitis-b-(hepb3)-immunization-coverage-among-1-year-olds-(-)
[23]	World Health Organization. Only 45% of babies received the hepatitis B vaccine within 24 hours of birth in 2022.[EB/OL].( 2024-04-09)[ 2024-09-21]. https://www.who.int/multi-media/details/only-45percent-of-babies-received-the-hepatitis-b-vaccine-within-24-hours-of-birth-in-2022. https://www.who.int/multi-media/details/only-45percent-of-babies-received-the-hepatitis-b-vaccine-within-24-hours-of-birth-in-2022
[24]	World Health Organization. Implementing the global health sector strategies on HIV, viral hepatitis and sexually transmitted infections, 2022- 2030: Report on progress and gaps 2024, second edition[EB/OL].( 2024-07-22)[ 2024-09-21]. https://www.who.int/publications/i/item/9789240097872. https://www.who.int/publications/i/item/9789240097872
[25]	ZHANG BF, CHENG ML, ZHANG Q, et al. Clinical study on blocking mother-to-child transmission of hepatitis B virus with high viral load and HBeAg positivity during pregnancy in Guizhou province[J]. Chin J Hepatol, 2018, 26( 12): 945- 950. DOI: 10.3760/cma.j.issn.1007-3418.2018.12.013. 张宝芳, 程明亮, 张权, 等. 贵州地区HBeAg阳性乙型肝炎病毒高载量孕妇母婴阻断的临床研究[J]. 中华肝脏病杂志, 2018, 26( 12): 945- 950. DOI: 10.3760/cma.j.issn.1007-3418.2018.12.013.
[26]	YI W, CAO XZ, ZENG Z, et al. Developmental consequences of children born from mothers with telbivudine treatment during late pregnancy: A prospective study with 3-year follow-up[J]. Virulence, 2021, 12( 1): 1527- 1537. DOI: 10.1080/21505594.2021.1936769.
[27]	ZHU B, LV XJ, ZHAO ZY, et al. Comparison of the efficacy and safety of tenofovir and telbivudine in interrupting mother-to-child transmission of hepatitis B virus[J]. Medicine(Baltimore), 2021, 100( 44): e27695. DOI: 10.1097/MD.0000000000027695.
[28]	WANG M, RAN R, ZHU YX, et al. Comparison of tenofovir disoproxil fumarate and telbivudine in preventing hepatitis B transmission in mothers with high viral load[J]. Int J Gynaecol Obstet, 2023, 160( 2): 646- 652. DOI: 10.1002/ijgo.14341.
[29]	ZHENG H, ZHANG GM, CHAN PL, et al. Compliance among infants exposed to hepatitis B virus in a post-vaccination serological testing program in four provinces in China[J]. Infect Dis Poverty, 2019, 8( 1): 57. DOI: 10.1186/s40249-019-0568-y.
[30]	World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection[EB/OL].( 2024-03-29)[ 2024-09-21]. https://www.who.int/publications/i/item/9789240090903. https://www.who.int/publications/i/item/9789240090903
[31]	Infectious Diseases Physicians Branch, Chinese Medical Doctor Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Chinese practice guideline for the prevention and treatment of mother-to-child transmission of hepatitis B virus(version 2024)[J]. J Clin Hepatol, 2024, 40( 8): 1557- 1566. DOI: 10.12449/JCH240809. 中国医师协会感染科医师分会, 中华医学会感染病学分会. 中国乙型肝炎病毒母婴传播防治指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 8): 1557- 1566. DOI: 10.12449/JCH240809.
[32]	GUO HJ, GAO YF, LIU HY, et al. Impact of cessation of antiviral therapy at delivery on postpartum liver function in mothers with chronic hepatitis B virus infection[J]. Chin J Hepatol, 2019, 27( 2): 112- 117. DOI: 10.3760/cma.j.issn.1007-3418.2019.02.008. 郭辉杰, 高云飞, 刘惠媛, 等. 妊娠期抗病毒治疗的慢性乙型肝炎病毒感染孕妇分娩时停药对产后肝功能的影响[J]. 中华肝脏病杂志, 2019, 27( 2): 112- 117. DOI: 10.3760/cma.j.issn.1007-3418.2019.02.008.
[33]	World Health Organization. Global health sector strategies on HIV, viral hepatitis and sexually transmitted infections for the period 2022- 2030[EB/OL].( 2022-07-18)[ 2024-09-21]. https://www.who.int/publications/i/item/9789240053779. https://www.who.int/publications/i/item/9789240053779
[34]	CUI FQ, SHEN LP, LI L, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China[J]. Emerg Infect Dis, 2017, 23( 5): 765- 772. DOI: 10.3201/eid2305.161477.
[35]	YIN XR, WANG W, CHEN H, et al. Real-world implementation of a multilevel interventions program to prevent mother-to-child transmission of HBV in China[J]. Nat Med, 2024, 30( 2): 455- 462. DOI: 10.1038/s41591-023-02782-x.
[36]	WANG AL, QIAO YP, DOU LX, et al. Challenges of eliminating mother-to-child transmission of HIV, syphilis and hepatitis B in China: A cross-sectional survey[J]. Lancet, 2018, 392: S55. DOI: 10.1016/S0140-6736(18)32684-9.
[37]	World Health Organization. Guidance for country validation of viral hepatitis elimination and path to elimination[EB/OL].( 2023-10-05)[ 2024-09-21]. https://www.who.int/publications/i/item/9789240078635. https://www.who.int/publications/i/item/9789240078635
[38]	ZHENG H, WANG FZ, ZHANG GM, et al. Cost-benefit analysis of the hepatitis B vaccination to prevent mother-to-child transmission strategies in China, 1992-2019[J]. Chin J Epidemiol, 2021, 42( 9): 1537- 1545. DOI: 10.3760/cma.j.cn112338-20210319-00226. 郑徽, 王富珍, 张国民, 等. 中国1992—2019年乙型肝炎疫苗免疫及母婴阻断策略的成本效益分析[J]. 中华流行病学杂志, 2021, 42( 9): 1537- 1545. DOI: 10.3760/cma.j.cn112338-20210319-00226.
[39]	WANG AL, SUN H, WANG Q, et al. Challenges and prospects of eliminating AIDS, syphilis and mother-to-child transmission of hepatitis B in China[J]. Chin J AIDS STD, 2023, 29( 8): 845- 847. DOI: 10.13419/j.cnki.aids.2023.08.01. 王爱玲, 孙贺, 王前, 等. 中国消除艾滋病梅毒和乙肝母婴传播的挑战与展望[J]. 中国艾滋病性病, 2023, 29( 8): 845- 847. DOI: 10.13419/j.cnki.aids.2023.08.01.
[40]	PATTON H, TRAN TT. Management of hepatitis B during pregnancy[J]. Nat Rev Gastroenterol Hepatol, 2014, 11( 7): 402- 409. DOI: 10.1038/nrgastro.2014.30.
[41]	ZHOU LY, LIU XT, OU XT, et al. Chronic hepatitis B in women of childbearing age and pregnant women in China: A cross-sectional study[J]. Am J Trop Med Hyg, 2024, 110( 4): 719- 723. DOI: 10.4269/ajtmh.23-0217.
[42]	BOUCHERON P, LU Y, YOSHIDA K, et al. Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: A systematic review and meta-analysis[J]. Lancet Infect Dis, 2021, 21( 1): 85- 96. DOI: 10.1016/S1473-3099(20)30593-4.
[43]	CHALID MT, TURYADI, SI IE, et al. A cautionary note to hepatitis B e antigen(HBeAg)-negative test results in pregnant women in an area prevalent of HBeAg-negative chronic hepatitis B[J]. J Med Virol, 2023, 95( 1): e28125. DOI: 10.1002/jmv.28125.
[44]	PLATT L, FRENCH CE, CR McGOWAN et al. Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis[J]. J Viral Hepat, 2020, 27( 3): 294- 315. DOI: 10.1111/jvh.13217.
[45]	World Health Organization. Criteria for validation of elimination of viral hepatitis B and C: report of 7 country pilots[EB/OL].( 2022-09-01)[ 2024-09-21]. https://www.who.int/publications/i/item/9789240055292. https://www.who.int/publications/i/item/9789240055292

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (138) PDF downloads(51)

Advances and challenges in eliminating mother-to-child transmission of hepatitis B virus worldwide

DOI: 10.12449/JCH241104

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Advances and challenges in eliminating mother-to-child transmission of hepatitis B virus worldwide

DOI: 10.12449/JCH241104

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content